| Year |
Citation |
Score |
| 2018 |
Husain SA, Willey JZ, Park Moon Y, Elkind MSV, Sacco RL, Wolf M, Cheung K, Wright CB, Mohan S. Creatinine- versus cystatin C-based renal function assessment in the Northern Manhattan Study. Plos One. 13: e0206839. PMID 30427947 DOI: 10.1371/Journal.Pone.0206839 |
0.357 |
|
| 2016 |
Souma N, Isakova T, Lipiszko D, Sacco RL, Elkind MS, DeRosa JT, Silverberg SJ, Mendez AJ, Dong C, Wright CB, Wolf M. Fibroblast Growth Factor 23 and Cause-Specific Mortality in the General Population: The Northern Manhattan Study. The Journal of Clinical Endocrinology and Metabolism. jc20162215. PMID 27501282 DOI: 10.1210/Jc.2016-2215 |
0.394 |
|
| 2016 |
Wright CB, Shah NH, Mendez AJ, DeRosa JT, Yoshita M, Elkind MS, Sacco RL, DeCarli C, Rundek T, Silverberg S, Dong C, Wolf M. Fibroblast Growth Factor 23 Is Associated With Subclinical Cerebrovascular Damage: The Northern Manhattan Study. Stroke; a Journal of Cerebral Circulation. PMID 26956260 DOI: 10.1161/Strokeaha.115.012379 |
0.399 |
|
| 2015 |
Shah NH, Dong C, Elkind MS, Sacco RL, Mendez AJ, Hudson BI, Silverberg S, Wolf M, Rundek T, Wright CB. Fibroblast Growth Factor 23 Is Associated With Carotid Plaque Presence and Area: The Northern Manhattan Study. Arteriosclerosis, Thrombosis, and Vascular Biology. PMID 26112008 DOI: 10.1161/Atvbaha.115.305945 |
0.418 |
|
| 2014 |
Wright CB, Dong C, Stark M, Silverberg S, Rundek T, Elkind MS, Sacco RL, Mendez A, Wolf M. Plasma FGF23 and the risk of stroke: the Northern Manhattan Study (NOMAS). Neurology. 82: 1700-6. PMID 24706015 DOI: 10.1212/Wnl.0000000000000410 |
0.395 |
|
| Show low-probability matches. |